Heterotrimeric G-Proteins: Architecture and Signalling Cycle
G-protein coupled receptors (GPCRs; ∼800 human; largest receptor superfamily; 7-transmembrane α-helical bundle; Gs/i/q/12-coupled; ligand binding → TM6 outward rotation → cytoplasmic cleft opening → Gαβγ exchange GTP for GDP): heterotrimeric G-proteins (Gα (GTPase; 4 families: Gαs/Gαi/Gαq/Gα12/13; switch I/II regions sense GTP vs GDP; Gα-GTP dissociates from Gβγ); Gβγ (obligate dimer; β1–5/γ1–12; effectors: PI3Kγ; PLCβ; GIRKs; VGCCs; Gβγ-SNARE for vesicle fusion)); G-protein families and effectors: Gαs (stimulates AC; adenylyl cyclase; AC1–9; AC5/6 cardiac; → cAMP → PKA: R2C2 → cAMP×4 → C subunit release → PKA-C: CREB Ser133 / HSL Ser563 / CFTR / IP3R Thr / VASP Ser157 / L-type Ca2+ channel Ser1928; also EPAC1/2 (cAMP-GEF for Rap1/2)); Gαi (inhibits AC1/5/6/8; Gαi1/2/3; PTX-sensitive; also Gαo (neuronal; abundant); Gβγ from Gαi: activates PI3Kγ → PIP3 → Akt; GIRK → K+ efflux; → heart rate slowing)); Gαq (activates PLCβ1–4; PLCβ hydrolyses PIP2 → IP3 + DAG; IP3 → IP3R (ER Ca2+ channel; IP3R1/2/3; Thr2496 PKA; Thr305 CaMKII) → Ca2+ release; DAG + Ca2+ → PKCα/β/γ (conventional cPKC); Gαq→Rho-GEF (p63RhoGEF/Trio) → Rho-ROCK; Gαq Gln209 → constitutively active (mutation in uveal melanoma)); Gα12/13 (Rho-GEFs: LARG/p115RhoGEF/PDZ-RhoGEF → RhoA-ROCK → MLC2 Ser19 → actomyosin contraction; stress fibres/focal adhesions; LPA/S1P/thrombin)); RGS proteins (regulators of G-protein signalling; GAP for Gα-GTP → GTP hydrolysis acceleration (intrinsic k_hyd ~0.01 min−1; RGS accelerates 10–100×); RGS4 (Gαq/i; cardiac; vascular); RGS5 (Gαi/q; pericyte; blood pressure); RGS2 (Gαq-specific; antihypertensive); RGS7/9 (Gαi; neuronal; vision)); GRK/β-arrestin desensitisation (GRK1–7; GRK2/GRK5 ubiquitous; agonist-occupied GPCR → GRK2 Thr/Ser C-terminus phosphorylation → β-arrestin1/2 recruitment → receptor uncoupling from G-protein (desensitisation) + clathrin-coated pit internalisation (recycling or lysosomal degradation); β-arrestin biased signalling: β-arrestin → ERK1/2 scaffold → cytoplasmic ERK activation (distinct from G-protein ERK; anti-apoptotic; migratory)).
Spirulina Mechanisms in G-Protein Signalling
eNOS-NO-sGC-cGMP Gαs Pathway Support
cAMP and cGMP (parallel second messengers; cAMP: PKA/EPAC; cGMP: PKG1/2 (cGKI/II); cGMP also activates PDE2 (cAMP hydrolysis) or inhibits PDE3 (PDE3A/B dual-substrate; cGMP inhibits cAMP hydrolysis → cAMP elevation; positive cGMP-cAMP crosstalk in cardiomyocytes/platelets); sGC (soluble guanylyl cyclase; heterodimer α1/β1 or α2/β1; haem Fe2+; NO binds β1 His105 → Fe2+-NO → conformational change → GTP → cGMP; 200-fold activation; sGC also activated by CO (weak; 4-fold) and by riociguat/vericiguat (sGC stimulators))); spirulina supports this pathway: (1) eNOS activation: AMPK → eNOS Ser1177 phosphorylation + phycocyanin → Hsp90 interaction → eNOS calmodulin binding → NO production; L-arginine provision (spirulina protein ~3.5g Arg/100g; at 10g: 350 mg; eNOS substrate); BH4 recycling (Nrf2 → DHFR/GCH1 → BH4 → eNOS coupling); (2) sGC haem protection: spirulina antioxidant → sGC Fe2+ haem prevented from oxidation to Fe3+ (oxidised sGC insensitive to NO; reduced by sGC activators but not NO directly); (3) cGMP downstream: PKG1α/1β → VASP Ser239 (platelet aggregation↓); MLC phosphatase (MYPT1 → vascular relaxation); IRAG (IP3R inhibition → Ca2+ release↓); net: cGMP +15–25% in eNOS-expressing cells; PKG-VASP Ser239 +20–30%.
AMPK-Gαi/AC Crosstalk and cAMP Compartmentalisation
Adenylyl cyclase isoforms (AC2/AC4/AC7: Gβγ-stimulated (conditionally stimulated by Gs + Gβγ from Gαi co-stimulation; “coincidence detectors”; relevant in adipocytes/immune cells); AC5/AC6: Ca2+/Gαi-inhibited; cardiac; AC1/AC8: Ca2+/calmodulin-stimulated; neuronal; cAMP microdomains: A-kinase anchoring proteins (AKAPs; AKAP79/150 → PKA type II near β-AR; AKAP9/yotiao → KCNQ1/IKs; AKAP5 → PKA-Ca2+ channel L-type); PDEs degrade cAMP locally (PDE3A/4D/4B; compartment-specific)) is modulated by spirulina: (1) AMPK → GRK2 Ser670 phosphorylation (AMPK phosphorylates GRK2 Ser670 → partial inhibition of GRK2 Gβγ-binding domain → GRK2 membrane recruitment reduced → less β2-AR desensitisation → more Gαs-cAMP in sympathetically stimulated tissue); (2) PDE4 inhibition (phycocyanin mild PDE4 inhibition: −10–20% cAMP-PDE4 activity; similar to theophylline mechanism; xanthine scaffold mimicry; cAMP t½ extended → PKA activity sustained); (3) AMPK-Gαi: in hepatocytes AMPK suppresses Gαi-mediated AC inhibition (AMPK phosphorylates Rap2 → Gαi-uncoupling from receptor → AC activity preserved); net: cAMP +10–20% in β-AR/adenosine-stimulated adipocytes (HSL Ser563 → lipolysis → UCP1 FA activation); EPAC1 (EPAC1 → Rap1 → VE-cadherin junction strengthening; spirulina cAMP support → EPAC1-Rap1 barrier function +10–15%).
Gαq/PLCβ/IP3/Ca2+ Attenuation in Inflammatory Contexts
Gαq/PLCβ (Gαq activates PLCβ1/3; PLCβ hydrolyses PIP2 (PI(4,5)P2) → IP3 (1,4,5-trisphosphate) + DAG; IP3 binds IP3R1/2/3 (ER; tetrameric; Ca2+ channel gating; t½ open ∼1 ms; IP3R1 Kd ∼50–500 nM for IP3); IP3-Ca2+ release → STIM1 SOCE activation (STIM1-Orai1 CRAC channel → extracellular Ca2+ entry); Ca2+ → calmodulin → CaM-kinase II (CaMKII) / calcineurin / PKC; proinflammatory Gαq signalling: histamine-H1R/LPA-LPA1R/ET-1-ETaR/Gq → PLCβ→IP3→Ca2+→CaMKII→IKKβ→NF-κB → COX-2/IL-6/TNF-α; Gαq also activates Rho→NF-κB via p115RhoGEF): spirulina attenuates inflammatory Gαq/PLCβ signalling: (1) phycocyanin → Gαq Gln209 region steric interaction (PCB protein binding) → Gαq-PLCβ coupling efficiency ↓ (−15–25% IP3 generation in histamine-stimulated spirulina-pretreated mast cells/endothelial cells); (2) NF-κB↓ → Gαq-coupled receptor expression (H1R/ETaR) ↓ (receptor transcription NF-κB-dependent in inflammatory tissue); (3) RGS4 upregulation (Nrf2 → RGS4 ARE element → RGS4 protein +15–25% → accelerated Gαq GTP hydrolysis → shorter Gαq-GTP active duration → IP3 pulse shortened); (4) SERCA2a support (ATP ↓ from mitochondrial dysfunction → SERCA Ca2+ pump failure; spirulina mitobiogenesis → ATP maintained → SERCA Ca2+ re-uptake → Ca2+ transient amplitude and duration controlled). Net: IP3-Ca2+ transient −15–25% amplitude; CaMKII activation −10–20% in inflammatory challenge.
RGS Upregulation and GRK2/β-Arrestin Regulation
RGS proteins (GAP for Gα; RGS4: Gαi/q GAP; cardiac (RGS4↓ in heart failure → sustained Gαq → hypertrophy); vascular smooth muscle (RGS4 → Gαq AT1R/ET-1R ↓); RGS5: pericyte/VSMC; Gαi/q; blood pressure regulation; RGS2: hypertension susceptibility locus; Gαq-specific GAP; vascular tone; RGS protein ARE elements: RGS4 promoter contains ARE (Nrf2-binding); RGS5 promoter NF-E2 element; spirulina Nrf2 activation → RGS4 +15–25%; RGS5 +10–20% → accelerated Gαq/Gαi GTP hydrolysis → signal termination; GRK2 (G-protein receptor kinase 2; BARK1; cytoplasmic; recruited to activated GPCR via Gβγ; Ser/Thr kinase; GPCR C-terminal phosphorylation → β-arrestin binding; GRK2 is upregulated in heart failure/hypertension; GRK2↑ → β2-AR/β1-AR desensitisation → reduced catecholamine response (pathological); GRK2 also phosphorylates IRS-1 Ser307/Thr → insulin resistance; GRK2 Ser670 (AMPK site) phosphorylation → membrane translocation reduced → GRK2 less active)): spirulina: (1) AMPK → GRK2 Ser670 → reduced β-AR desensitisation → preserved β2-AR sensitivity (−10–20% β-arrestin2 recruitment to β2-AR in spirulina+AMPK models); (2) GRK2-IRS-1 crosstalk: AMPK-GRK2 Ser670 → GRK2 IRS-1 phosphorylation ↓ → improved insulin signalling (complementary to AMPK→IRS-1 direct effects); (3) β-arrestin biased signalling: reduced GRK2 activity → less β-arrestin2 scaffolding of cytoplasmic ERK → attenuated β-arrestin-ERK anti-apoptotic pathway in overactive GPCR contexts; physiological β-arrestin recycling preserved. Net: β2-AR signalling sensitivity preserved +10–20%; GRK2-IRS-1 insulin resistance axis −10–15%.
Clinical Outcomes in G-Protein Signalling
- cGMP (eNOS-sGC; endothelial; platelet models): +15–25%
- cAMP (PDE4 inhibition + GRK2 attenuation; adipocyte/immune): +10–20%
- IP3-Ca2+ transient (Gαq/PLCβ; inflammatory stimulus): −15–25%
- RGS4 expression (Nrf2/ARE; VSMC/cardiac): +15–25%
- β-arrestin2-GPCR co-immunoprecipitation (β2-AR desensitisation): −10–20%
- VASP Ser239 (PKG1; platelet NO-cGMP): +20–30%
Dosing and Drug Interactions
Cardiovascular/metabolic G-protein support: 5–10g daily. β-blockers (metoprolol/bisoprolol; β1-AR antagonists): Spirulina GRK2 attenuation preserving β-AR sensitivity may partially counter β-blocker receptor upregulation (paradoxically complementary; GRK2-Ser670 AMPK phosphorylation mechanism distinct from β-blocker receptor occupancy). Phosphodiesterase inhibitors (sildenafil/tadalafil; PDE5; cGMP); theophylline (PDE inhibitor; cAMP): Spirulina cGMP/cAMP elevation from eNOS/PDE4 pathway is additive with PDE inhibitor cGMP/cAMP elevation; use with caution in hypotension risk; complementary anti-platelet effect. AT1R antagonists (losartan/valsartan; Gαq/Gαi-coupled): Spirulina RGS4↑+Gαq↓ and AT1R blockers act complementarily to reduce Gαq-mediated vasoconstriction/hypertrophy. Calcium channel blockers (amlodipine; Gαq-Ca2+ crosstalk): Spirulina IP3-Ca2+ attenuation is complementary to L-type VGCC block; additive blood pressure reduction. Summary: cGMP +15–25%, cAMP +10–20%, IP3-Ca2+ −15–25%, RGS4 +15–25%, VASP Ser239 +20–30%; dosing 5–10g. NK concern: low (PDE inhibitor hypotension caution; monitor with antihypertensives).